Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 6/20 | 0.38 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.38 |
| ▸ | PARP11 | Q9NR21 | 2/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.31 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.31 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.31 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.31 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.31 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.31 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.31 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3243204 | 0.84 | LIG1 (0.42) | SRCPARP1PARP10PARP11PDPK1 | |
| SCHEMBL6246982 | 0.82 | SRC (0.39) | SRCPARP1PARP10PARP11PDPK1 | |
| SCHEMBL9667622 | 0.82 | ALDH1A1 (0.45) | SRCPARP1PARP10PARP11PDPK1 | |
| Hydrochloric Acid SCHEMBL30075334 | 0.82 | LIG1 (0.41) | SRCPARP1PARP10PARP11PDPK1 | |
| SCHEMBL3384120 | 0.82 | AURKA (0.50) | SRCPARP1PARP10PARP11PDPK1 | |
| SCHEMBL24210987 | 0.79 | SRC (0.36) | SRCPARP1PARP10PARP11PDPK1 | |
| SCHEMBL6244960 | 0.78 | PLK1 (0.44) | SRCPARP1PARP10PARP11PDPK1 | |
| SCHEMBL10661545 | 0.78 | KDM4E (0.45) | SRCPARP1TSHRKDM4EALDH1A1 | |
| SCHEMBL31562070 | 0.78 | KDM4E (0.45) | SRCPARP1TSHRKDM4EALDH1A1 | |
| SCHEMBL10544590 | 0.78 | AKR1C3 (0.46) | PARP1PARP10PARP11PDPK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1984002-B1 | TRIALKYLSILYLBENZYLAMINOCARBOXYINDOLES, INDAZOLES AND INDOLINES AND THEIR USE IN TREATING CETP-MEDIATED DISORDERS | HOFFMANN LA ROCHE (CH) | 2010-12-22 | — | — | EP | disclosed |
| US-7572823-B2 | Heteroaryl carboxamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7259183-B2 | Indole, indazole and indoline derivatives as CETP inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2007-08-21 | — | — | US | disclosed |
| US-20070185182-A1 | Heteroaryl carboxamide compounds | HOFFMAN-LA ROCHE INC. | 2007-08-09 | — | — | US | disclosed |
| US-20060030613-A1 | Indole, indazole and indoline derivatives as CETP inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030613-A1 | Indole, indazole and indoline derivatives as CETP inhibitors | CETP, NAT1, MTTP | SRC 3494/4885PARP1 118/4885PARP10 312/4885 |
| US-20070185182-A1 | Heteroaryl carboxamide compounds | ABCB1, ABCG2, CYP3A43 | SRC 2222/4885PARP1 467/4885PARP10 696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.